Immunodiagnostic Systems Hldgs PLC Partnership Agreement with Technogenetics (9460B)
16 January 2018 - 6:00PM
UK Regulatory
TIDMIDH
RNS Number : 9460B
Immunodiagnostic Systems Hldgs PLC
16 January 2018
16 January 2018
Immunodiagnostic Systems Holdings plc
Partnership Agreement with Technogenetics srl
Immunodiagnostic Systems Holdings plc ("IDS"), a specialist
producer of manual and automated diagnostic testing kits and
instruments for the clinical market, today announces that it has
reached agreement with Technogenetics srl ("TGS") to enable IDS to
sell TGS's range of assay kits under the IDS brand, on a global
basis.
TGS produces a broad range of CE approved CLIA automated assay
kits for use in the fields of autoimmune and infectious disease
diagnostics, which have been developed for the IDS iSYS analyser.
This agreement follows a more restricted arrangement where IDS sold
a limited number of the TGS assays in a small number of European
countries. The new agreement, which runs for an initial period of
ten years, gives IDS the right, subject to obtaining the necessary
regulatory approvals, to sell the kits under the IDS brand on a
worldwide basis.
Jaap Stuut, CEO of IDS commented:
"We are delighted to have reached this agreement, and look
forward to working with the team at TGS as we commercialize the IDS
iSYS Autoimmune and Infectious Disease assay portfolio. We now have
access to a further 50 assays in additional territories which will
complement our existing endocrinology portfolio and add to our
competitive position as a result of the increased menu on the IDS
iSYS.
During the next financial year we will focus on obtaining
regulatory approval outside Europe for these assays and on driving
further commercialisation as soon as possible."
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660
Jaap Stuut, CEO
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
About Technogenetics srl :
TGS is an innovative company that has been active for over 30
years in the areas of diagnostic research and biotechnology. Since
December 2015, TGS is part of the KHB Group, headquartered in
Shanghai, and is engaged in complex and ambitious challenges with
the aim of offering the market increasingly efficient and advanced
diagnostic solutions. KHB is listed on the Shenzhen Stock
Exchange.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRUVSARWSAAAUR
(END) Dow Jones Newswires
January 16, 2018 02:00 ET (07:00 GMT)
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Apr 2024 to May 2024
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From May 2023 to May 2024